Kite to Showcase Leading CAR T-Cell Therapies at ASH 2024, Featuring Positive Survival Outcomes

Kite, a subsidiary of Gilead Sciences, will present data on its CAR T-cell therapy portfolio at the American Society of Hematology (ASH) Annual Meeting and Exposition. The presentations will focus on various blood cancers and include six oral sessions. Dr. Dominique Tonelli, Kite's Global Head of Medical Affairs, emphasized the company's dedication to advancing blood cancer treatments through CAR T-cell therapy.

Kite and its partner, Arcellx, will present significant findings on anitocabtagene autoleucel (anito-cel) for relapsed/refractory multiple myeloma (R/R MM). Data from a Phase 1 study shows a median progression-free survival (PFS) of 30.2 months, with a median follow-up of 38.1 months. Additionally, in the Phase 2 iMMagine-1 study, preliminary results from 58 patients indicate a 95% objective response rate (ORR) and a 62% complete response/ stringent complete response (CR/sCR) at a median follow-up of 10.3 months. Notably, these studies have not reported delayed neurotoxicities, such as parkinsonism or Guillain-Barre syndrome.

Kite will also showcase positive survival outcomes with Yescarta and Tecartus. Yescarta (axicabtagene ciloleucel) has demonstrated superior overall survival compared to standard therapy in patients with early relapsed/refractory large B-cell lymphoma (R/R LBCL). The five-year follow-up from the ZUMA-5 trial will highlight the treatment's long-term efficacy in R/R indolent non-Hodgkin lymphoma (iNHL). Furthermore, research on improvements in Yescarta manufacturing for R/R LBCL patients will be discussed.

Tecartus (brexucabtagene autoleucel) will be the focus of presentations on five-year outcomes from ZUMA-2 cohorts, showcasing durable responses in adult patients with R/R mantle cell lymphoma (MCL). Additionally, real-world outcomes for Tecartus in adults with R/R B-cell precursor acute lymphoblastic leukemia (B-ALL) will be presented, underlining the therapy's effectiveness in a broader patient population.

The pipeline advancements include data on Kite's next-generation CAR T-cell therapy, KITE-753, an autologous anti-CD19/CD20 therapy for B-cell malignancies. Kite is also collaborating with numerous institutions, such as The Lymphoma Study Association and Dana-Farber Cancer Institute, to provide further insights into CAR T-cell therapies.

Oral presentations at the ASH meeting will cover various aspects of axicabtagene ciloleucel (Axi-Cel) therapy, including real-world early outcomes, trends in cytokine release syndrome and neurologic events, predictors of early safety outcomes, and a five-year follow-up analysis from the ZUMA-5 trial. Brexucabtagene autoleucel (Brexu-Cel) will also be the subject of a primary analysis of ZUMA-2 cohort 3, focusing on patients with R/R MCL who were naive to Bruton tyrosine kinase inhibitors (BTKi). The Phase 2 registrational study of anitocabtagene autoleucel for treating R/R MM will also be highlighted.

Poster presentations at the ASH meeting will include topics such as treatment patterns in large B-cell lymphoma, improvements in axicabtagene ciloleucel manufacturing, impacts of inflammation and tumor attributes on clinical outcomes, and real-world outcomes for Brexucabtagene autoleucel in R/R MCL patients. Additional posters will address the efficacy and safety of anitocabtagene autoleucel in R/R MM, Kite's next-generation CAR T-cell therapies, and investigator-sponsored studies.

Kite's robust presence at the ASH meeting underscores its commitment to advancing CAR T-cell therapies and improving outcomes for patients with blood cancers. The comprehensive data presented aim to reinforce the therapeutic potential and long-term benefits of CAR T-cell treatments in managing various hematologic malignancies.